Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients

Cancer Detection and Prevention

Volumn 31, Issue 5, 2007, Pages 402-407

  Beneduce, Luca ^a   Prayer Galetti, Tommaso ^b   Giustinian, Andrea Marcello Grimani ^a   Gallotta, Andrea ^a   Betto, Giovanni ^b   Pagano, Francesco ^c   Fassina, Giorgio ^a  

^a Xeptagen SpA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

Cancer diagnosis; Cancer immune surveillance; Immunoglobulin M immune complexes; Multivalent IgM; Natural immunity; Prostate; Prostate specific antigen (PSA); PSA IgM

Indexed keywords

IMMUNOGLOBULIN M; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; ASSAY; CANCER DIAGNOSIS; CANCER PATIENT; CHEMOLUMINESCENCE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNITY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SEROLOGY; SERUM;

ANTIGEN-ANTIBODY COMPLEX; AREA UNDER CURVE; CHROMATOGRAPHY, GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN M; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 36448933410     PISSN: 0361090X     EISSN: 15251500     Source Type: Journal    
DOI: 10.1016/j.cdp.2007.10.005     Document Type: Article

References (27)

1. Ward A.M., Catto J.W., and Hamdy F.C. Prostate specific antigen: biology, biochemistry and available commercial assays. Ann Clin Biochem 38 (2001) 633-651
2. Semjonow A., Brandt B., Oberpenning F., Roth S., and Hertle L. Discordance of assay methods creates pitfalls for the interpretation of prostate specific antigen values. Prostate Suppl 7 (1996) 3-16
3. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350 (2004) 2239-2246
4. Stenman U.H., Leinonen J., Alfthan H., Ranniko S., Tuhkanen K., and Alfthan O. A complex between prostate specific antigen and alpha-1-chymo-trypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51 (1991) 222-226
5. Catalona W.J., Partin A.W., Slawin K.M., Brawer M.K., Flanigan R.C., Patel A., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279 (1998) 1542-1547
6. Benson M.C., Whang I.S., Pantuck A., Ring K., Kaplan S.A., Olsson C.A., et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 147 (1992) 815-816
7. Carter H.B., Pearson J.D., Metter E.J., Brant L.J., Chan D.W., Andres R., et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 267 (1992) 2215-2220
8. Oesterling J.E., Jacobsen S.J., Chute C.G., Guess H.A., Girman C.J., Panser L.A., et al. Serum prostate specific antigen in a community based population of healthy men: establishment of age-specific reference ranges. JAMA 270 (1993) 860-864
9. Brawer M.K. Assays for complexed prostate specific antigen and other advances in the diagnosis of prostate cancer. Rev Urol 5 Suppl. 6 (2003) S10-S16
10. Pontisso P., Calabrese F., Benvegnu L., Lise M., Belluco C., Ruvoletto M.G., et al. Overexpression of squamous cell carcinoma antigen variants in hepatocellular carcinoma. Br J Cancer 90 (2004) 833-837
11. Beneduce L., Castaldi F., Marino M., Tono N., Gatta A., Pontisso P., et al. Improvement of liver cancer detection with simultaneous assessment of circulating levels of free alpha-fetoprotein (AFP) and AFP-IgM complexes. Int J Biol Markers 19 (2004) 155-159
12. Beneduce L., Castaldi F., Marino M., Quarta S., Ruvoletto M., Benvegnu L., et al. Squamous cell carcinoma antigen-IgM complexes as novel biomarkers for hepatocellular carcinoma. Cancer 103 (2005) 2558-2565
13. Pontisso P., Quarta S., Caberlotto C., Beneduce L., Marino M., Bernardinello E., et al. Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma. Int J Cancer 119 (2006) 735-740
14. Castaldi F., Marino M., Beneduce L., Belluco C., De Marchi F., Mammano E., et al. Detection of circulating CEA-IgM complexes in early stage (stage 1) colorectal cancer. Int J Biol Markers 20 (2005) 204-208
15. Gleason D.F., and Mellinger G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111 (1974) 58-64
16. In: Sobin L.H., and Wittekind C.H. (Eds). TNM classification of malignant tumours. 6th ed. (2002), Wiley-Liss, New York
17. Wang X., Yu J., Sreekumar A., Varambally S., Shen R., Giacherio D., et al. Autoantibody signatures in prostate cancer. N Engl J Med 353 (2005) 1224-1235
18. Nesterova M., Johnson N., Cheadle C., and Cho-Chung Y.S. Autoantibody biomarker opens a new gateway for cancer diagnosis. Biochim Biophys Acta 1762 (2006) 398-403
19. Volmmers H.P., and Brandlein S. The "early birds": natural IgM antibodies and immune surveillance. Histol Histopathol 20 (2005) 927-937
20. Zitvogel L., Tesniere A., and Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 10 (2006) 715-727
21. Fuchs C., Krapf F., Kern P., Hoferichter S., Jager W., and Kalden J.R. CEA-containing immune complexes in sera of patients with colorectal and breast cancer-analysis of complexed immunoglobulin classes. Cancer Immunol Immunother 26 (1988) 180-184
22. Habal N., Gupta R.K., Bilchick A.J., Johnson T., and Morton D.L. TA90-IC, a new marker for advanced colon cancer. Ann Surg Oncol 7 (2000) 352-356
23. Croce M.V., Isla-Larrain M.T., Demichelis S.O., Gori J.R., Price M.R., and Segal-Eiras A. Tissue and serum MUC1 mucin detection in breast cancer patients. Breast Cancer Res Treat 81 (2003) 195-207
24. Peyrat J.P., Bonneterre J., Lubin R., Vanlemmens L., Fournier J., and Soussi T. Prognostic significance of circulating p53 antibodies in patients undergoing surgery for loco-regional breast cancer. Lancet 345 (1995) 621-622
25. Lacroix-Desmazes S., Kaveri S.V., Mouthon L., Ayouba A., Malanchere E., Coutinho A., et al. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods 216 (1998) 117-137
26. Varambally S., Bar-Dayan Y., Bayry J., Lacroix-Desmazes S., Horn M., Sorel M., et al. Natural human polyreactive IgM induce apoptosis of lymphoid cell lines and human peripheral blood mononuclear cells. Int Immunol 16 (2004) 517-524
27. Partin A.W., Catalona W.J., Southwick P.C., Subong E.N.P., Gasior G.H., and Chan D.W. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 48 (1996) 55-61